Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2013

01-02-2013 | Epidemiology

Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis

Authors: P. Hadji, V. Ziller, J. Kyvernitakis, M. Bauer, G. Haas, N. Schmidt, K. Kostev

Published in: Breast Cancer Research and Treatment | Issue 1/2013

Login to get access

Abstract

Compliance and persistence are often underestimated in breast cancer (BC) treatment. The aim of our study was to analyze the persistence with tamoxifen (TAM) and aromatase inhibitors (AI) in postmenopausal women with hormone-receptor-positive BC and to identify determinants of non-persistence. We used data of the Disease Analyzer database (IMS HEALTH, Germany) including 2,067 general practices and 397 gynecological practices. Out of a dataset of 15 million patients, we identified BC patients with a first-time TAM or AI prescriptions from October 2001 to December 2010. For persistence analyses, 12,412 women on tamoxifen, 2,796 on anastrozole, 647 on exemestane, and 1,657 on letrozole met the inclusion/exclusion criteria. Within 3 years of follow-up, the discontinuation rates increased to 52.2 % for tamoxifen, 47 % for anastrozole, 55.1 % for exemestane, and 44.3 % for letrozole treated women. A minor proportion of patients switched to a different endocrine treatment; 33 % tamoxifen, 20 % anastrozole, 22.9 % exemestane, and 23 % letrozole. The multivariate hazard ratios of the cox regression models showed that patients younger than 50 were most likely to discontinue initial therapy when compared with the reference group of women over 70 (p < 0.001). In contrast, patients treated in gynecologist practice had significantly longer persistence than patients who obtained their prescriptions in general practitioner practice (p < 0.001). In addition, the presence of the co morbidities like diabetes (p < 0.001) or depression (p < 0.002) was also associated with decreased risk of treatment discontinuation. Persistence with all endocrine treatments in women with hormone-receptor-positive BC is low and needs to be significantly increased to improved outcome in clinical practice. Further research is required to understand this complex issue.
Literature
1.
go back to reference Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46(4):765–781PubMedCrossRef Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46(4):765–781PubMedCrossRef
3.
go back to reference Carlson RW, Allred DC, Anderson BO et al (2011) Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 7(2):122–192 Carlson RW, Allred DC, Anderson BO et al (2011) Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 7(2):122–192
4.
go back to reference EBCTCG (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717CrossRef EBCTCG (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717CrossRef
5.
go back to reference Partridge AH, Avorn J, Wang PS et al (2002) Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 94:652–661PubMedCrossRef Partridge AH, Avorn J, Wang PS et al (2002) Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 94:652–661PubMedCrossRef
6.
go back to reference Buzdar AU, Coombes RC, Goss PE et al (2008) Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Cancer 112:700–709PubMedCrossRef Buzdar AU, Coombes RC, Goss PE et al (2008) Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Cancer 112:700–709PubMedCrossRef
7.
go back to reference Chlebowski R, Cuzick J, Amakye D et al (2009) Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer. Breast 18(Suppl 2):S1–S11PubMedCrossRef Chlebowski R, Cuzick J, Amakye D et al (2009) Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer. Breast 18(Suppl 2):S1–S11PubMedCrossRef
8.
go back to reference Rao RD, Cobleigh MA (2012) Adjuvant endocrine therapy for breast cancer. Oncology (Williston Park) 26(6):541–547 Rao RD, Cobleigh MA (2012) Adjuvant endocrine therapy for breast cancer. Oncology (Williston Park) 26(6):541–547
9.
go back to reference Burstein HJ, Prestrud AA, Seidenfeld J et al (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784–3796PubMedCrossRef Burstein HJ, Prestrud AA, Seidenfeld J et al (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784–3796PubMedCrossRef
10.
go back to reference Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62PubMedCrossRef Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62PubMedCrossRef
11.
go back to reference Forbes JF, Cuzick J, Buzdar A et al (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100 month analysis of the ATAC trial. Lancet Oncol 9:45–53PubMedCrossRef Forbes JF, Cuzick J, Buzdar A et al (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100 month analysis of the ATAC trial. Lancet Oncol 9:45–53PubMedCrossRef
12.
go back to reference World Health Organization (2003) Adherence to long-term therapies: evidence for action. World Health Organization, Geneva, pp 129–136 World Health Organization (2003) Adherence to long-term therapies: evidence for action. World Health Organization, Geneva, pp 129–136
13.
go back to reference Hadji P (2008) Menopausal symptoms and adjuvant therapy-associated adverse events. Endocr Relat Cancer 15:73–90PubMedCrossRef Hadji P (2008) Menopausal symptoms and adjuvant therapy-associated adverse events. Endocr Relat Cancer 15:73–90PubMedCrossRef
14.
go back to reference Balkrishnan R (2005) The importance of medication adherence in improving chronic-disease related outcomes: what we know and what we need to further know. Med Care 43:517–520PubMedCrossRef Balkrishnan R (2005) The importance of medication adherence in improving chronic-disease related outcomes: what we know and what we need to further know. Med Care 43:517–520PubMedCrossRef
15.
go back to reference Davidson B, Vogel V, Wickerham L (2007) Oncologist-patient discussion of adjuvant hormonal therapy in breast cancer: results of a linguistic study focusing on adherence and persistence to therapy. J Support Oncol 5:139–143PubMed Davidson B, Vogel V, Wickerham L (2007) Oncologist-patient discussion of adjuvant hormonal therapy in breast cancer: results of a linguistic study focusing on adherence and persistence to therapy. J Support Oncol 5:139–143PubMed
16.
go back to reference Andrade SE, Kahler KH, Frech F, Chan KA (2006) Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 15:565–574PubMedCrossRef Andrade SE, Kahler KH, Frech F, Chan KA (2006) Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 15:565–574PubMedCrossRef
17.
go back to reference Dezii CM (2001) Persistence with drug therapy: a practical approach using administrative claims data. Manag Care 10:42–45PubMed Dezii CM (2001) Persistence with drug therapy: a practical approach using administrative claims data. Manag Care 10:42–45PubMed
18.
go back to reference Grunfeld EA, Hunter MS, Sikka P et al (2005) Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 59:97–102PubMedCrossRef Grunfeld EA, Hunter MS, Sikka P et al (2005) Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 59:97–102PubMedCrossRef
19.
go back to reference Horne R, Weinman J (1999) Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 47:555–567PubMedCrossRef Horne R, Weinman J (1999) Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 47:555–567PubMedCrossRef
22.
go back to reference Hadji P (2010) Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol 73:156–166PubMedCrossRef Hadji P (2010) Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol 73:156–166PubMedCrossRef
23.
go back to reference Ziller V, Kalder M, Albert US, Holzhauer W, Ziller M, Wagner U, Hadji P (2009) Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 20(3):431–436PubMedCrossRef Ziller V, Kalder M, Albert US, Holzhauer W, Ziller M, Wagner U, Hadji P (2009) Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 20(3):431–436PubMedCrossRef
24.
go back to reference Kostev K, Haas G (eds) (2011) Medical care in Germany. Optimus, Göttingen, pp 1–4 Kostev K, Haas G (eds) (2011) Medical care in Germany. Optimus, Göttingen, pp 1–4
25.
go back to reference Becher H, Kostev K, Schröder-Bernhardi D (2009) Validity and representativeness of the Disease Analyzer patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharm Therap 47:617–626 Becher H, Kostev K, Schröder-Bernhardi D (2009) Validity and representativeness of the Disease Analyzer patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharm Therap 47:617–626
26.
go back to reference Ogdie A, Langan S, Parkinson J, Dattani H, Kostev K, Gelfand JM (2012) Medical Record Databases. In: Strom BL, Kimmel S, Hennessy S (eds) Pharmacoepidemiology, 5th edn. University of Pennsylvania, Philadelphia, pp 224–243 Ogdie A, Langan S, Parkinson J, Dattani H, Kostev K, Gelfand JM (2012) Medical Record Databases. In: Strom BL, Kimmel S, Hennessy S (eds) Pharmacoepidemiology, 5th edn. University of Pennsylvania, Philadelphia, pp 224–243
27.
go back to reference Hadji P, Claus V, Steinle T, Intorcia M, Kostev K, Ziller V GRAND: The German retrospective cohort analysis on non-adherence and associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int 10 Feb 2011 (Epub ahead of print) PMID: 21308365 Hadji P, Claus V, Steinle T, Intorcia M, Kostev K, Ziller V GRAND: The German retrospective cohort analysis on non-adherence and associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int 10 Feb 2011 (Epub ahead of print) PMID: 21308365
28.
go back to reference Henneicke-von Zepelin H, Meden H, Meden H, Kostev K, Schröder-Bernhardi D, Stammwitz U, Becher H (2007) Isopropanolic black cohosh extract and recurrence-free survival after breast cancer. Int J Clin Pharm Therap 45(3):143–154 Henneicke-von Zepelin H, Meden H, Meden H, Kostev K, Schröder-Bernhardi D, Stammwitz U, Becher H (2007) Isopropanolic black cohosh extract and recurrence-free survival after breast cancer. Int J Clin Pharm Therap 45(3):143–154
29.
go back to reference Motheral B, Brooks J, Clark MA, Crown WH, Davey P, Hutchins D et al (2003) A checklist for retrospective database studies—report of the ISPOR task force on retrospective databases. Value Health 6:90–97PubMedCrossRef Motheral B, Brooks J, Clark MA, Crown WH, Davey P, Hutchins D et al (2003) A checklist for retrospective database studies—report of the ISPOR task force on retrospective databases. Value Health 6:90–97PubMedCrossRef
30.
go back to reference Partridge AH, LaFountain A, Mayer E et al (2008) Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26:556–562PubMedCrossRef Partridge AH, LaFountain A, Mayer E et al (2008) Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26:556–562PubMedCrossRef
31.
go back to reference Sedjo RL, Devine S (2010) Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat 125:191–200PubMedCrossRef Sedjo RL, Devine S (2010) Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat 125:191–200PubMedCrossRef
32.
go back to reference Partridge AH, Wang PS, Winer EP, Avorn J (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21:6002–6006CrossRef Partridge AH, Wang PS, Winer EP, Avorn J (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21:6002–6006CrossRef
33.
go back to reference Huiart L, Bouhnik AD, Rey D, Tarpin C, Cluze C, Bendiane MK, Viens P, Giorgi R (2012) Early discontinuation of tamoxifen intake in younger women with breast cancer: is it time to rethink the way it is prescribed? Eur J Cancer 48(13):1939–1946PubMedCrossRef Huiart L, Bouhnik AD, Rey D, Tarpin C, Cluze C, Bendiane MK, Viens P, Giorgi R (2012) Early discontinuation of tamoxifen intake in younger women with breast cancer: is it time to rethink the way it is prescribed? Eur J Cancer 48(13):1939–1946PubMedCrossRef
34.
go back to reference Wigertz A, Ahlgren J, Holmqvist M, Fornander T, Adolfsson J, Lindman H, Bergkvist L, Lambe M (2012) Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study. Breast Cancer Res Treat 133(1):367–373PubMedCrossRef Wigertz A, Ahlgren J, Holmqvist M, Fornander T, Adolfsson J, Lindman H, Bergkvist L, Lambe M (2012) Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study. Breast Cancer Res Treat 133(1):367–373PubMedCrossRef
35.
go back to reference Nekhlyudov L, Li L, Ross-Degnan D, Wagner AK (2011) Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer. Breast Cancer Res Treat 130(2):681–689PubMedCrossRef Nekhlyudov L, Li L, Ross-Degnan D, Wagner AK (2011) Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer. Breast Cancer Res Treat 130(2):681–689PubMedCrossRef
36.
go back to reference Danilak M, Chambers CR (2012) Adherence to adjuvant endocrine therapy in women with breast cancer. J Oncol Pharm Pract 15 Aug 2012 (Epub ahead of print) Danilak M, Chambers CR (2012) Adherence to adjuvant endocrine therapy in women with breast cancer. J Oncol Pharm Pract 15 Aug 2012 (Epub ahead of print)
37.
go back to reference Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Bluethmann SM, Vernon SW, Vernon SW (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134(2):459–478PubMedCrossRef Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Bluethmann SM, Vernon SW, Vernon SW (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134(2):459–478PubMedCrossRef
38.
go back to reference Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ (2007) Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 109:832–839PubMedCrossRef Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ (2007) Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 109:832–839PubMedCrossRef
39.
go back to reference Kahn KL, Schneider EC, Malin JL, Adams JL, Epstein AM (2007) Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care 45:431–439PubMedCrossRef Kahn KL, Schneider EC, Malin JL, Adams JL, Epstein AM (2007) Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care 45:431–439PubMedCrossRef
40.
go back to reference Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, Lin Gomez S, Fehrenbacher L, Miles S, Neugut AI (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8769 early-stage breast cancer patients. J Clin Oncol 28:4120–4128PubMedCrossRef Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, Lin Gomez S, Fehrenbacher L, Miles S, Neugut AI (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8769 early-stage breast cancer patients. J Clin Oncol 28:4120–4128PubMedCrossRef
41.
go back to reference Iwamoto J, Miyata A, Sato Y, Takeda T, Matsumoto H (2009) Factors affecting discontinuation of alendronate treatment in postmenopausal Japanese women with osteoporosis. J Chin Med Assoc 72(12):619–624PubMedCrossRef Iwamoto J, Miyata A, Sato Y, Takeda T, Matsumoto H (2009) Factors affecting discontinuation of alendronate treatment in postmenopausal Japanese women with osteoporosis. J Chin Med Assoc 72(12):619–624PubMedCrossRef
42.
go back to reference Himei A, Okamura T (2006) Discontinuation syndrome associated with paroxetine in depressed patients: a retrospective analysis of factors involved in the occurrence of the syndrome. CNS Drugs 20(8):665–672PubMedCrossRef Himei A, Okamura T (2006) Discontinuation syndrome associated with paroxetine in depressed patients: a retrospective analysis of factors involved in the occurrence of the syndrome. CNS Drugs 20(8):665–672PubMedCrossRef
Metadata
Title
Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis
Authors
P. Hadji
V. Ziller
J. Kyvernitakis
M. Bauer
G. Haas
N. Schmidt
K. Kostev
Publication date
01-02-2013
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2013
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-013-2417-1

Other articles of this Issue 1/2013

Breast Cancer Research and Treatment 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine